Amarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript

Karim Mikhail: Yes. For the UK price, so you have seen from the slide that we put sort of the prices of the multiple consumer — oral drugs in the UK on a list level. And we are very conscious that some of these list prices for other benchmarks is not really the net, meaning that, some of them are even discounting further to NHS to basically gain access. Where do we stand today? And based on our agreement, we are actually not discounting from this number that you see to NHS. So, this is for us, a big part of the strategy of why we believe that the negotiation we’ve had was very successful, because we convinced nice of the value of the product and that there was — it was not necessary for us to be discounting this. So, all the formulary listings that you’ve seen there do not actually involve additional discounts, right?

So, the list is the net and we feel very proud of that performance. And by the way, this is what’s positioning us to strong negotiations in the other markets, because the Spanish governments and everybody else can see and visualize our price in the UK and they understand exactly what the British government is paying for Amarin for VASCEPA.

Operator: We have reached the end of the question-and-answer session, and I’ll now turn a call over to Karim for closing remarks.

Karim Mikhail: Well, I just want to thank you all for your presence today and for the engagement throughout 2022, as we’ve said was a challenging year, but we’ve had a very significant turnaround and it’s only the beginning of a two evolution of Amarin. We look forward to stay connected throughout the quarters and to very soon be sharing with you our results in the first quarter. Thank you all for joining. Thank you.

Operator: This concludes today’s conference, and you may disconnect your lines at this time. Thank you for your participation.